Abstract

Lower-risk myelodysplastic syndromes are defined using prognostic scoring systems that incorporate data on bone marrow blast percentage, degree and numbers of cytopenias, and cytogenetic abnormalities. Increasingly, these are incorporating molecular abnormalities to further refine risk. Therapy is geared toward predominating cytopenias, with erythropoiesis-stimulating agents luspatercept and lenalidomide used to ameliorate anemia, romiplostim and eltrombopag tackling thrombocytopenia, and hypomethylating agents and antithymocyte globulin palliating pancytopenia. Newer agents on the horizon are abrogating the downstream sequelae of specific molecular mutations. One challenge for the future is in further modifying response criteria to align with improvements that are clinically meaningful to patients.

References

References
1.
Makishima
H
,
Yoshizato
T
,
Yoshida
K
, et al
.
Dynamics of clonal evolution in myelodysplastic syndromes
.
Nat Genet
.
2017
;
49
(
2
):
204
-
212
.
2.
Haferlach
T
,
Nagata
Y
,
Grossmann
V
, et al
.
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
.
Leukemia
.
2014
;
28
(
2
):
241
-
247
.
3.
Noone
AM
,
Howlader
N
,
Krapcho
M
, et al
, eds.
SEER Cancer Statistics Review, 1975-2015, National Cancer Institute
.
Bethesda, MD
:
National Cancer Institute
;
2018
.
4.
Sekeres
MA
,
Schoonen
WM
,
Kantarjian
H
, et al
.
Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys
.
J Natl Cancer Inst
.
2008
;
100
(
21
):
1542
-
1551
.
5.
Greenberg
P
,
Cox
C
,
LeBeau
MM
, et al
.
International scoring system for evaluating prognosis in myelodysplastic syndromes
.
Blood
.
1997
;
89
(
6
):
2079
-
2088
.
6.
Greenberg
PL
,
Tuechler
H
,
Schanz
J
, et al
.
Revised international prognostic scoring system for myelodysplastic syndromes
.
Blood
.
2012
;
120
(
12
):
2454
-
2465
.
7.
Nazha
A
,
Al-Issa
K
,
Hamilton
BK
, et al
.
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
.
Leukemia
.
2017
;
31
(
12
):
2848
-
2850
.
8.
Nazha
A
,
Komrokji
RS
,
Meggendorfer
M
, et al
.
A personalized prediction model to risk stratify patients with myelodysplastic syndromes [abstract]
.
Blood
.
2018
;
132
(
suppl 1
):
793
.
9.
Bejar
R
,
Stevenson
K
,
Abdel-Wahab
O
, et al
.
Clinical effect of point mutations in myelodysplastic syndromes
.
N Engl J Med
.
2011
;
364
(
26
):
2496
-
2506
.
10.
Platzbecker
U
,
Fenaux
P
,
Adès
L
, et al
.
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
.
Blood
.
2019
;
133
(
10
):
1020
-
1030
.
11.
Golshayan
AR
,
Jin
T
,
Maciejewski
J
, et al
.
Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes
.
Br J Haematol
.
2007
;
137
(
2
):
125
-
132
.
12.
Hellström-Lindberg
E
,
Gulbrandsen
N
,
Lindberg
G
, et al;
Scandinavian MDS Group
.
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life
.
Br J Haematol
.
2003
;
120
(
6
):
1037
-
1046
.
13.
Platzbecker
U
,
Symeonidis
A
,
Oliva
EN
, et al
.
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
.
Leukemia
.
2017
;
31
(
9
):
1944
-
1950
.
14.
Platzbecker
U
,
Germing
U
,
Götze
KS
, et al
.
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
.
Lancet Oncol
.
2017
;
18
(
10
):
1338
-
1347
.
15.
Fenaux
P
,
Platzbecker
U
,
Mufti
GJ
, et al
.
The Medalist trial: results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept to treat anemia in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions [abstract]
.
Blood
.
2018
;
132
(
suppl 1
):
1
.
16.
Giagounidis
AA
,
Germing
U
,
Haase
S
, et al
.
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31
.
Leukemia
.
2004
;
18
(
1
):
113
-
119
.
17.
Bernasconi
P
,
Klersy
C
,
Boni
M
, et al
.
Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution
.
Leukemia
.
2005
;
19
(
8
):
1424
-
1431
.
18.
Schanz
J
,
Tüchler
H
,
Solé
F
, et al
.
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge
.
J Clin Oncol
.
2012
;
30
(
8
):
820
-
829
.
19.
List
A
,
Dewald
G
,
Bennett
J
, et al;
Myelodysplastic Syndrome-003 Study Investigators
.
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
.
N Engl J Med
.
2006
;
355
(
14
):
1456
-
1465
.
20.
List
AF
,
Bennett
JM
,
Sekeres
MA
, et al;
MDS-003 Study Investigators
.
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS [published correction appears in Leukemia. 2015;29(12):2452]
.
Leukemia
.
2014
;
28
(
5
):
1033
-
1040
.
21.
Fenaux
P
,
Giagounidis
A
,
Selleslag
D
, et al;
MDS-004 Lenalidomide del5q Study Group
.
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
.
Blood
.
2011
;
118
(
14
):
3765
-
3776
.
22.
Sekeres
MA
,
Swern
AS
,
Giagounidis
A
, et al
.
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
.
Blood Cancer J
.
2018
;
8
(
10
):
90
.
23.
Raza
A
,
Reeves
JA
,
Feldman
EJ
, et al
.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
.
Blood
.
2008
;
111
(
1
):
86
-
93
.
24.
Santini
V
,
Almeida
A
,
Giagounidis
A
, et al
.
Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents
.
J Clin Oncol
.
2016
;
34
(
25
):
2988
-
2996
.
25.
Giagounidis
A
,
Mufti
GJ
,
Fenaux
P
, et al
.
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia
.
Cancer
.
2014
;
120
(
12
):
1838
-
1846
.
26.
Oliva
EN
,
Alati
C
,
Santini
V
, et al
.
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
.
Lancet Haematol
.
2017
;
4
(
3
):
e127
-
e136
.
27.
Garcia-Manero
G
,
Jabbour
E
,
Borthakur
G
, et al
.
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes
.
J Clin Oncol
.
2013
;
31
(
20
):
2548
-
2553
.
28.
Saunthararajah
Y
,
Sekeres
M
,
Advani
A
, et al
.
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes
.
J Clin Invest
.
2015
;
125
(
3
):
1043
-
1055
.
29.
Jabbour
E
,
Short
NJ
,
Montalban-Bravo
G
, et al
.
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
.
Blood
.
2017
;
130
(
13
):
1514
-
1522
.
30.
Passweg
JR
,
Giagounidis
AA
,
Simcock
M
, et al
.
Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99
.
J Clin Oncol
.
2011
;
29
(
3
):
303
-
309
.
31.
Komrokji
RS
,
Mailloux
AW
,
Chen
DT
, et al
.
A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction
.
Haematologica
.
2014
;
99
(
7
):
1176
-
1183
.
32.
Buonamici
S
,
Yoshimi
A
,
Thomas
M
, et al
.
H3B-8800, an orally bioavailable modulator of the SF3b complex, shows efficacy in spliceosome-mutant myeloid malignancies [abstract]
.
Blood
.
2016
;
128
(
22
):
966
.
33.
Lambert
JM
,
Gorzov
P
,
Veprintsev
DB
, et al
.
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
.
Cancer Cell
.
2009
;
15
(
5
):
376
-
388
.
34.
Sallman
DA
,
DeZern
AE
,
Steensma
DP
, et al
.
Phase 1b/2 combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [abstract]
.
Blood
.
2018
;
132
(
suppl 1
):
3091
.
35.
Cheson
BD
,
Greenberg
PL
,
Bennett
JM
, et al
.
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
.
Blood
.
2006
;
108
(
2
):
419
-
425
.
36.
Sekeres
MA
,
Steensma
DP
.
Rethinking clinical trial endpoints in myelodysplastic syndromes
.
Leukemia
.
2019
;
33
(
3
):
570
-
575
.
37.
Ramsey
SD
,
McCune
JS
,
Blough
DK
, et al
.
Patterns of blood product use among patients with myelodysplastic syndrome
.
Vox Sang
.
2012
;
102
(
4
):
331
-
337
.
38.
Tefferi
A
,
Al-Ali
HK
,
Barosi
G
, et al
.
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence [published correction appears in Leukemia. 2017;31(5):1252]
.
Leukemia
.
2017
;
31
(
4
):
896
-
902
.
You do not currently have access to this content.

Comments

0 Comments